ABUS vs OKE · P/E 5.4, rev $6.2M vs P/E 15, rev $21.70B
Arbutus Biopharma Corp (ABUS) versus ONEOK Inc (OKE) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
ONEOK Inc (OKE) is a oil & gas midstream company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported OKE revenue for 2024-12-31 was $21.70B. Net income was $3.11B. Revenue was up 22.7% from 2023-12-31 to 2024-12-31. OKE currently screens at market cap $53.92B and trailing P/E 15.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. OKE currently screens at market cap $53.92B and trailing P/E 15.3.
Not investment advice. Open the ABUS and OKE stock pages for the full models.
Not investment advice.